PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
PRMT5 是 CDK4/6 抑制剂耐药性 ER+/RB 缺陷型乳腺癌的可行治疗靶点
期刊:Nature Communications
影响因子:14.7
doi:10.1038/s41467-024-46495-2
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram Mani, David W Cesc